Skip to main content
SpringerLink
Log in
Book cover

Nuclear Oncology pp 1–13Cite as

Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications

  • 123 Accesses

Abstract

The armamentarium of approved radiopharmaceuticals for either diagnosis or therapy is at the core of the clinical practice of today’s nuclear medicine. Nevertheless, both because the currently approved agents do not meet all the clinical needs for radionuclide targeting and because advancing knowledge in the pathophysiology of tissues/organs open in turn new opportunities, investigations continue at the preclinical and clinical validation level for the development of new radiopharmaceuticals, most of which are not approved yet for commercial use. Concerning in particular the diagnostic applications of nuclear medicine to oncology, ongoing investigations in the search for tumor-targeting agents with better specificity and sensitivity are countless, possibly within the scenario of theranostics – that is, with the dual potential for imaging and for therapy, depending on the specific radionuclide employed for radiolabeling. We will focus this chapter on the most promising imaging agents labeled with single-photon-emitting radionuclides based on some of the mechanisms that are typical for tumor cells/tissues.

This is a preview of subscription content, log in via an institution.

Abbreviations

BTAP:

Bis(thioacetamido)pentanoyl

DOTA:

2-(4-Isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (macrocyclic coupling agent to label compounds of biological interest with metal radionuclides)

DTPA:

Diethylenetriaminepentaacetic acid

EGF:

Epidermal growth factor

EGFR:

Epidermal growth factor receptor

FDA:

United States Food and Drug Administration

GMP:

Good manufacturing practice

HER:

Human epidermal growth factor receptor

HPLC:

High-performance liquid chromatography (formerly known as high-pressure liquid chromatography)

HYNIC:

6-Hydrazinopyridine-3-carboxylic acid, also known as hydrazidonicotinic acid/hydrazinonicotinamide (a chelating agent)

MMP:

Metalloproteinases, a family of matrix enzymes

MRI:

Magnetic resonance imaging

NIRF:

Near-infrared fluorescence

PET:

Positron emission tomography

RGD:

Tripeptide composed of L-arginine, glycine, and L-aspartic acid (a sequence that is a common element in cellular recognition)

SPECT:

Single-photon emission tomography

TGF:

Transforming growth factor

TKI:

Tyrosine kinase inhibitor

TPPTS:

3,3,3”-Phosphanetriyltris(benzenesulfonic acid) trisodium salt, a ligand also known as sodium triphenylphosphine trisulfonate

VEGF:

Vascular endothelial growth factor

References

  1. Ravdin P. The use of HER2 testing in the management of breast cancer. Semin Oncol. 2000;27 Suppl 9:33–42.

    CAS  PubMed  Google Scholar 

  2. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405(6788):857–65.

    Article  CAS  PubMed  Google Scholar 

  3. Cornelissen B. Imaging the inside of a tumour: a review of radionuclide imaging and theranostics targeting intracellular epitopes. J Label Compd Radiopharm. 2014;57:310–6.

    Article  CAS  Google Scholar 

  4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  PubMed  Google Scholar 

  5. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. The immune hallmarks of cancer. Cancer Immunol Immunother. 2011;60:319–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012;92:897–965.

    Article  CAS  PubMed  Google Scholar 

  7. Mariani G, Bruselli L, Duatti A. Is PET always an advantage versus planar and SPECT? Eur J Nucl Med Mol Imaging. 2008;35:1560–5.

    Article  PubMed  Google Scholar 

  8. Pauwels EKJ, Bergstrom K, Mariani G, Kairemo K. Microdosing, imaging biomarkers and SPECT: a multi-sided tripod to accelerate drug development. Curr Pharm Des. 2009;15:928–34.

    Article  CAS  PubMed  Google Scholar 

  9. Mariani G, Strauss HW. Positron emission and single-photon emission imaging: synergy rather than competition. Eur J Nucl Med Mol Imaging. 2011;38:1189–90.

    Article  PubMed  Google Scholar 

  10. Vaupel P. Pathophysiology of solid tumors. In: Molls M, Vaupel P, Nieder C, Anscher MS, editors. The impact of tumor biology on cancer treatment and multidisciplinary strategies. Heidelberg: Springer; 2009. p. 51–92.

    Chapter  Google Scholar 

  11. Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer. 2000;36:675–81.

    Article  CAS  PubMed  Google Scholar 

  12. Zhou Y, Chakraborty S, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics. 2011;1:58–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tsiapa I, Loudos G, Varvarigou A, Fragogeorgi E, Psimadas D, Tsotakos T, et al. Biological evaluation of an ornithine-modified 99mTc-labeled RGD peptide as an angiogenesis imaging agent. Nucl Med Biol. 2013;40:262–72.

    Article  CAS  PubMed  Google Scholar 

  14. Kimura S, Umeda IO, Moriyama N, Fujii H. Synthesis and evaluation of a novel 99mTc-labeled bioreductive probe for tumor hypoxia imaging. Bioorg Med Chem Lett. 2011;21:7359–62.

    Article  CAS  PubMed  Google Scholar 

  15. Umeda IO, Tani K, Tsuda K, Kobayashi M, Ogata M, Kimura S, et al. High resolution SPECT imaging for visualization of intratumoral heterogeneity using a SPECT/CT scanner dedicated for small animal imaging. Ann Nucl Med. 2012;26:67–76.

    Article  PubMed  Google Scholar 

  16. Weerakkody D, Moshnikova A, Thakur MS, Moshnikova V, Daniels J, Engelman DM, et al. Family of pH (low) insertion peptides for tumor targeting. Proc Natl Acad Sci U S A. 2013;110:5834–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. von Forstner C, Zuhayra M, Ammerpohl O, Zhao Y, Tiwari S, Jansen O, et al. Expression of L amino acid transport system 1 and analysis of iodine-123-methyltyrosine tumor uptake in a pancreatic xenotransplantation model using fused high-resolutionmicro-SPECT-MRI. Hepatobiliary Pancreat Dis Int. 2011;10:30–7.

    Article  Google Scholar 

  18. Kondo N, Temma T, Shimizu Y, Watanabe H, Higano K, Takagi Y, et al. Miniaturized antibodies for imaging membrane type-1 matrix metalloproteinase in cancers. Cancer Sci. 2013;104:495–501.

    Article  CAS  PubMed  Google Scholar 

  19. LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, et al. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res. 2013;73:2070–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cai J, Li F. Single-photon emission computed tomography tracers for predicting and monitoring cancer therapy. Curr Pharm Biotechnol. 2013;14:693–707.

    Article  CAS  PubMed  Google Scholar 

  21. Schottelius M, Wester HJ. Molecular imaging targeting peptide receptors. Methods. 2009;48:161–77.

    Article  CAS  PubMed  Google Scholar 

  22. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Bouwman WH, van der Graaf WT, Oyen WJ, et al. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab′)2 and Fab fragments of the monoclonal antibody R1507. Mol Pharm. 2012;9:2314–21.

    CAS  PubMed  Google Scholar 

  23. Muller C. Folate based radiopharmaceuticals for imaging and therapy of cancer and inflammation. Curr Pharm Des. 2012;18:1058–83.

    Article  CAS  PubMed  Google Scholar 

  24. Kassis AI, Adelstein SJ, Mariani G. Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Q J Nucl Med. 1996;40:301–19.

    CAS  PubMed  Google Scholar 

  25. Mariani G, Bodei L, Adelstein SJ, Kassis AI. Emerging roles for radiometabolic therapy of tumors based on Auger electron emission. J Nucl Med. 2000;41:1519–21.

    CAS  PubMed  Google Scholar 

  26. Adelstein SJ, Kassis AI, Bodei L, Mariani G. Radiotoxicity of iodine-125 and other Auger-electron emitting radionuclides: background to therapy. Cancer Biother Radio-Pharm. 2003;18:301–16.

    Article  CAS  Google Scholar 

  27. Bodei L, Kassis AI, Adelstein SJ, Mariani G. Radionuclide therapy with iodine-125 and other Auger-electron-emitting radionuclides: experimental models and clinical applications. Cancer Biother Radiopharm. 2003;18:861–77.

    Article  CAS  PubMed  Google Scholar 

  28. Aloj L, Aurilio M, Rinaldi V, D’Ambrosio L, Tesauro D, Peitl PK, et al. Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging. 2011;38:1417–25.

    Article  CAS  PubMed  Google Scholar 

  29. Forrer F, Valkema R, Bernard B, Schramm NU, Hoppin JW, Rolleman E, et al. In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals. Eur J Nucl Med Mol Imaging. 2006;33:1214–7.

    Article  CAS  PubMed  Google Scholar 

  30. Behr TM, Béhé M, Becker W. Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med. 1999;43:268–80.

    CAS  PubMed  Google Scholar 

  31. Behr TM, Béhé MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97–109.

    Article  PubMed  Google Scholar 

  32. Quinn T, Zhang X, Miao Y. Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues. G Ital Dermatol Venereol. 2010;145:245–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52:42S–55.

    Article  CAS  PubMed  Google Scholar 

  34. Graham MM, Menda Y. Radiopeptide imaging and therapy in the United States. J Nucl Med. 2011;52:56S–63.

    Article  CAS  PubMed  Google Scholar 

  35. Tang B, Yong X, Xie R, Li QW, Yang SM. Vasoactive intestinal peptide receptor-based imaging and treatment of tumors. Int J Oncol. 2014;44:1023–31.

    CAS  PubMed  Google Scholar 

  36. Hubalewska-Dydejczyk A, Sowa-Staszczak A, Tomaszuk M, Stefańska A. GLP-1 and exendin-4 for imaging endocrine pancreas. A review. Labelled glucagon-like peptide-1 analogues: past, present and future. Q J Nucl Med Mol Imaging. 2015;59:152–60.

    CAS  PubMed  Google Scholar 

  37. Yang MY, Chuang H, Chen RF, Yang KD. Reversible phosphatidylserine expression on blood granulocytes related to membrane perturbation but not DNA strand breaks. J Leukoc Biol. 2002;71:231–7.

    CAS  PubMed  Google Scholar 

  38. Bouter A, Carmeille R, Gounou C, Bouvet F, Degrelle SA, Evain-Brion D, et al. Review: annexin-A5 and cell membrane repair. Placenta. 2015;36 Suppl 1:S43–9.

    Article  CAS  PubMed  Google Scholar 

  39. Gottlieb RA. Part III: molecular and cellular hematology apoptosis. In: Lichtman MA, Beutler E, Kipps TJ, editors. Williams’ hematology. 7th ed. New York: McGraw-Hill Book; 2007. p. 125–30.

    Google Scholar 

  40. Ogawa K, Aoki M. Radiolabeled apoptosis imaging agents for early detection of response to therapy. Sci World J. 2014;2014:732603. doi:10.1155/2014/732603. Epub 2014 Oct 14.

    Article  CAS  Google Scholar 

  41. Blankenberg FG. In vivo detection of apoptosis. J Nucl Med. 2008;49 Suppl 2:81S–95.

    Article  CAS  PubMed  Google Scholar 

  42. Kemerink GJ, Liu X, Kieffer D, Ceyssens S, Mortelmans L, Verbruggen AM, et al. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J Nucl Med. 2003;44:947–52.

    CAS  PubMed  Google Scholar 

  43. Tait JF, Smith C, Blankenberg FG. Structural requirements for in vivo detection of cell death with 99mTc-annexin V. J Nucl Med. 2005;46:807–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, et al. Increased uptake of the apoptosis-imaging agent 99mTc recombinant human annexin v in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res. 2002;8:2766–74.

    CAS  PubMed  Google Scholar 

  45. Schaper FLWVJ, Reutelingsperger CP. 99mTc-HYNIC-annexin A5 in oncology: evaluating efficacy of anti-cancer therapies. Cancers. 2013;5:550–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Vangestel C, Peeters M, Mees G, Oltenfreiter R, Boersma HH, Elsinga PH, et al. In vivo imaging of apoptosis in oncology: an update. Mol Imaging. 2011;10:340–58.

    CAS  PubMed  Google Scholar 

  47. Vangestel C, Van de Wiele C, Van Damme N, Staelens S, Pauwels P, Reutelingsperger CP, Peeters M. 99mTc-(CO)3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. J Nucl Med. 2011;52:1786–94.

    Article  CAS  PubMed  Google Scholar 

  48. Lahorte CM, van de Wiele C, Bacher K, van den Bossche B, Thierens H, van Belle S, et al. Biodistribution and dosimetry study of 123I-rh-annexin v in mice and humans. Nucl Med Commun. 2003;24:871–80.

    CAS  PubMed  Google Scholar 

  49. Marconescu A, Thorpe PE. Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells. Biochim Biophys Acta. 1778;2008:2217–24.

    Google Scholar 

  50. Bevers EM, Comfurius P, Dekkers DWC, Zwaal RFA. Lipid translocation across the plasma membrane of mammalian cells. Biochim Biophys Acta. 1999;439:317–30.

    Article  Google Scholar 

  51. Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell. 4th ed. New York: Garland Science; 2002.

    Google Scholar 

  52. Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res. 1985;26:1015–35.

    CAS  PubMed  Google Scholar 

  53. Emoto K, Toyama-Sorimachi N, Karasuyama H, Inoue K, Umeda M. Exposure of phosphatidylethanolamine on the surface of apoptotic cells. Exp Cell Res. 1997;232:430–4.

    Article  CAS  PubMed  Google Scholar 

  54. Umeda M, Emoto K. Membrane phospholipid dynamics during cytokinesis: regulation of actin filament assembly by redistribution of membrane surface phospholipid. Chem Phys Lipids. 1999;101:81–91.

    Article  CAS  PubMed  Google Scholar 

  55. Mills JC, Stone NL, Erhardt J, et al. Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. J Cell Biol. 1998;140:627–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Hayashi F, Nagashima K, Terui Y, et al. The structure of PA48009: the revised structure of duramycin. J Antibiot (Tokyo). 1990;43:1421–30.

    Article  CAS  Google Scholar 

  57. Zimmermann N, Freund S, Fredenhagen A, et al. Solution structures of the lantibiotics duramycin B and C. Eur J Biochem. 1993;216:419–28.

    Article  CAS  PubMed  Google Scholar 

  58. Aoki Y, Uenaka T, Aoki J, et al. A novel peptide probe for studying the transbilayer movement of phosphatidylethanolamine. J Biochem. 1994;116:291–7.

    Article  CAS  PubMed  Google Scholar 

  59. Machaidze G, Ziegler A, Seelig J. Specific binding of Ro 09-0198 (cinnamycin) to phosphatidylethanolamine: a thermodynamic analysis. Biochemistry. 2002;41:1965–71.

    Article  CAS  PubMed  Google Scholar 

  60. Guder A, Wiedemann I, Sahl HG. Posttranslationally modified bacteriocins: the lantibiotics. Biopolymers. 2000;55:62–73.

    Article  CAS  PubMed  Google Scholar 

  61. Hosoda K, Ohya M, Kohno T, et al. Structure determination of an immunopotentiator peptide, cinnamycin, complexed with lysophosphatidylethanolamine by 1H-NMR1. J Biochem. 1996;119:226–30.

    Article  CAS  PubMed  Google Scholar 

  62. Kaletta C, Entian KD, Jung G. Prepeptide sequence of cinnamycin (Ro 09-0198): the first structural gene of a duramycin-type lantibiotic. Eur J Biochem. 1991;199:411–5.

    Article  CAS  PubMed  Google Scholar 

  63. Marki F, Hanni E, Fredenhagen A, et al. Mode of action of the lanthioninecontaining peptide antibiotics duramycin, duramycin B and C, and cinnamycin as indirect inhibitors of phospholipase A2. Biochem Pharmacol. 1991;42:2027–35.

    Article  CAS  PubMed  Google Scholar 

  64. Iwamoto K, Hayakawa T, Murate M, et al. Curvature-dependent recognition of ethanolamine phospholipids by duramycin and cinnamycin. Biophys J. 2007;93:1608–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Seelig J. Thermodynamics of lipid-peptide interactions. Biochim Biophys Acta. 1666;2004:40–50.

    Google Scholar 

  66. Zhao M, Li Z, Bugenhagen S. 99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe. J Nucl Med. 2008;49:1345–52.

    Article  CAS  PubMed  Google Scholar 

  67. Zhao M, Li Z. A single-step kit formulation for the 99mTc-labeling of HYNIC-Duramycin. Nucl Med Biol. 2012;39:1006–11.

    Article  CAS  PubMed  Google Scholar 

  68. Audi S, Li Z, Capacete J, Liu Y, Fang W, Shu LG, Zhao M. Understanding the in vivo uptake kinetics of a phosphatidylethanolamine-binding agent 99mTc-Duramycin. Nucl Med Biol. 2012;39:821–5.

    Article  CAS  PubMed  Google Scholar 

  69. Wang L, Wang F, Fang W, et al. The feasibility of imaging myocardial ischemic/reperfusion injury using 99mTc-labeled duramycin in a porcine model. Nucl Med Biol. 2015;42:198–204.

    Article  PubMed  CAS  Google Scholar 

  70. Zhang Y, Stevenson GD, Barber C, et al. Imaging of rat cerebral ischemia-reperfusion injury using 99mTc-labeled duramycin. Nucl Med Biol. 2013;40:80–8.

    Article  PubMed  CAS  Google Scholar 

  71. Clough AV, Audi SH, Haworth ST, Roerig DL. Differential lung uptake of 99mTc-hexamethylpropyleneamine oxime and 99mTc-duramycin in the chronic hyperoxia rat model. J Nucl Med. 2012;53:1984–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Audi SH, Jacobs ER, Zhao M, Roerig DL, Haworth ST, Clough AV. In vivo detection of hyperoxia-induced pulmonary endothelial cell death using 99mTc-duramycin. Nucl Med Biol. 2015;42:46–52.

    Article  CAS  PubMed  Google Scholar 

  73. Medhora MM, Haworth S, Liu Y, Narayanan J, Gao F, Zhao M, et al. Biomarkers for radiation pneumonitis using non-invasive molecular imaging. J Nucl Med. 2016;57:1296–301.

    Google Scholar 

  74. Johnson SE, Li Z, Liu Y, Moulder JE, Zhao M. Whole-body imaging of high-dose ionizing irradiation-induced tissue injuries using 99mTc-duramycin. J Nucl Med. 2013;54:1397–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Elvas F, Vangestel C, Rapic S, Verhaeghe J, Gray B, Pak K, et al. Characterization of [99mTc]duramycin as a SPECT imaging agent for early assessment of tumor apoptosis. Mol Imaging Biol. 2015;17:838–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Luo R, Niu L, Qiu F, Fang W, Fu T, Zhao M, et al. Monitoring apoptosis of breast cancer xenograft after paclitaxel treatment with 99mTc-labeled duramycin SPECT/CT. Mol Imaging. 2016;29:15. doi:10.1177/1536012115624918.

    Google Scholar 

  77. Elvas F, Boddaert J, Vengestel C, Pak K, Gray B, Kumar-Singh S, et al. 99mTc-Duramycin SPECT imaging of early tumor response to targeted therapy: a comparison with 18F-FDG PET. J Nucl Med. 2017;58:665–70.

    Google Scholar 

  78. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238:491–7.

    Article  CAS  PubMed  Google Scholar 

  79. Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, Milonakis A, Sirmalis G, et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med. 1998;25:1383–9.

    Article  CAS  PubMed  Google Scholar 

  80. Hua J, Dobrucki LW, Sadeghi MM, Zhang J, Bourke BN, Cavaliere P, et al. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation. 2005;111:3255–60.

    Article  CAS  PubMed  Google Scholar 

  81. Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med. 2006;47:1434–9.

    CAS  PubMed  Google Scholar 

  82. Bach-Gansmo T, Bogsrud TV, Skretting A. Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and 99mTc-labelled NC100692. Clin Physiol Funct Imaging. 2008;28:235–9.

    Article  PubMed  Google Scholar 

  83. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ, Study Group. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alphav beta3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol. 2010;51:40–6.

    Article  PubMed  Google Scholar 

  84. Dearling JL, Barnes JW, Panigrahy D, Zimmerman RE, Fahey F, Treves ST, et al. Specific uptake of 99mTc-NC100692, an αvβ3-targeted imaging probe, in subcutaneous and orthotopic tumors. Nucl Med Biol. 2013;40:788–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Shi J, Wang L, Kim YS, et al. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimmers with triglycine linkers. J Med Chem. 2008;51:7980–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Liu Z, Jia B, Shi J, et al. Tumor uptake of the RGD dimeric probe 99mTc-G3-2P4-RGD2 is correlated with integrin αVβ3 expressed on both tumor cells and neovasculature. Bioconjug Chem. 2010;21:548–55.

    Article  CAS  PubMed  Google Scholar 

  87. Zhou Y, Kim YS, Chakraborty S, Shi J, Gao H, Liu S. 99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin αVβ3 expression. Mol Imaging. 2011;10:386–97.

    PubMed  Google Scholar 

  88. Ma Q, Ji B, Jia B, et al. Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy. Eur J Nucl Med Mol Imaging. 2011;38:2145–52.

    Article  PubMed  Google Scholar 

  89. Liu L, Song Y, Gao S, Ji T, Zhang H, Ji B, et al. 99mTc-3PRGD2 scintimammography in palpable and nonpalpable breast lesions. Mol Imaging. 2014;13:1–7. doi:10.2310/7290.2014.00010.

    PubMed  PubMed Central  Google Scholar 

  90. Zhu Z, Miao W, Li Q, Dai H, Ma Q, Wang F, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med. 2012;53:716–22.

    Article  PubMed  Google Scholar 

  91. Zhao D, Jin X, Li F, Liang J, Lin Y. Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2. J Nucl Med. 2012;53:1872–7.

    Article  CAS  PubMed  Google Scholar 

  92. Miao W, Zheng S, Dai H, Wang F, Jin X, Zhu Z, Jia B. Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study. PLoS One. 2014;9(10):e111221.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Ji S, Zhou Y, Voorbach MJ, Shao G, Zhang Y, Fox GB, et al. Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2. J Pharmacol Exp Ther. 2013;346:251–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Liu Z, Huang J, Dong C, et al. 99mTc-labeled RGD-BBN peptide for small-animal SPET/CT of lung carcinoma. Mol Pharm. 2012;9:1409–17.

    CAS  PubMed  Google Scholar 

  95. Chen Q, Ma Q, Chen M, et al. An exploratory study on 99mTc-RGDBBN. Peptide scintimammography in the assessment of breast malignant lesions compared to 99mTc-3P4-RGD2. PLoS One. 2015;10(4):e0123401.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  96. Ji T, Sun Y, Chen B, Ji B, Gao S, Ma Q, et al. The diagnostic role of 99mTc-dual receptor targeted probe and targeted peptide bombesin (RGD-BBN) SPET/CT in the detection of malignant and benign breast tumors and axillary lymph nodes compared to ultrasound. Hell J Nucl Med. 2015;18:108–13.

    PubMed  Google Scholar 

  97. Bunschoten A, van Willigen DM, Buckle T, van den Berg NS, Welling MM, Spa SJ, Wester HJ, et al. Tailoring fluorescent dyes to optimize a hybrid RGD-tracer. Bioconjug Chem. 2016;27:1253–8.

    Article  CAS  PubMed  Google Scholar 

  98. Castellani P, Viale G, Dorcaratto A, Nicolò G, Kaczmarek J, Querze G, Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer. 1994;59:612–8.

    Article  CAS  PubMed  Google Scholar 

  99. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998;273:21769–76.

    Article  CAS  PubMed  Google Scholar 

  100. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L. A high-affinity human antibody that targets tumoral blood vessels. Blood. 1999;94:192–8.

    CAS  PubMed  Google Scholar 

  101. Berndorff D, Borkowski S, Moosmayer D, Viti F, Muller-Tiemann B, Sieger S, et al. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med. 2006;47:1707–16.

    CAS  PubMed  Google Scholar 

  102. Kaczmarek J, Castellani P, Nicolò G, Spina B, Allemanni G, Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer. 1994;59:11–6.

    Article  CAS  PubMed  Google Scholar 

  103. Pujuguet P, Hammann A, Moutet M, Samuel JL, Martin F, Martin M. Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor-associated myofibroblasts. Am J Pathol. 1996;148:579–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  104. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003;9:571–9.

    CAS  PubMed  Google Scholar 

  105. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111–22.

    CAS  PubMed  Google Scholar 

  106. Foda HD, Zucker S. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today. 2001;6:478–82.

    Article  CAS  PubMed  Google Scholar 

  107. Matusiak N, van Waarde A, Bischoff R, Oltenfreiter R, van de Wiele C, Dierckx RA, et al. Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT. Curr Pharm Des. 2013;19:4647–72.

    Article  CAS  PubMed  Google Scholar 

  108. Sihver W, Pietzsch J, Krause M, Baumann M, Steinbach J, Pietzsch HJ. Radiolabeled cetuximab conjugates for EGFR targeted cancer diagnostics and therapy. Pharmaceuticals (Basel). 2014;7:311–38.

    Article  CAS  Google Scholar 

  109. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183–232.

    Article  CAS  PubMed  Google Scholar 

  110. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11:689–708.

    Article  CAS  PubMed  Google Scholar 

  111. Schechter NR, Yang DJ, Azhdarinia A, Kohanim S, Wendt R, Oh CS, et al. Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs. 2003;14:49–56.

    Article  CAS  PubMed  Google Scholar 

  112. Schechter NR, Wendt RE, Yang DJ, Azhdarinia A, Erwin WD, Stachowiak AM, et al. Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. J Nucl Med. 2004;45:1683–7.

    CAS  PubMed  Google Scholar 

  113. Price EW, Zeglis BM, Cawthray JF, Ramogida CF, Ramos N, Lewis JS, et al. H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy. J Am Chem Soc. 2013;135:12707–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Razumienko EJ, Scollard DA, Reilly RM. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. J Nucl Med. 2012;53:1943–50.

    Article  CAS  PubMed  Google Scholar 

  115. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, et al. Phase I and imaging trial of indium-111 labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991;83:97–104.

    Article  CAS  PubMed  Google Scholar 

  116. Lam K, Scollard DA, Chan C, Levine MN, Reilly RM. Kit for the preparation of 111In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin). Appl Radiat Isot. 2014;95:135–42.

    Article  CAS  Google Scholar 

  117. McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, Reilly RM. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med. 2009;50:1340–8.

    Article  CAS  PubMed  Google Scholar 

  118. Müller C, Mindt TL, de Jong M, Schibli R. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy. Eur J Nucl Med Mol Imaging. 2009;36:938–46.

    Article  PubMed  CAS  Google Scholar 

  119. Müller C, Forrer F, Schibli R, Krenning EP, de Jong M. SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate. J Nucl Med. 2008;49:310–07.

    Article  PubMed  CAS  Google Scholar 

  120. Reber J, Struthers H, Betzel T, Hohn A, Schibli R, Müller C. Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast. Mol Pharm. 2012;9:1213–21.

    CAS  PubMed  Google Scholar 

  121. Maurer AH, Elsinga P, Fanti S, Nguyen B, Oyen WJ, Weber WA. Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging. J Nucl Med. 2014;55:701–4.

    Article  CAS  PubMed  Google Scholar 

  122. Morris RT, Joyrich RN, Naumann RW, Shah NP, Maurer AH, Strauss HW, et al. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). Ann Oncol. 2014;25:852–8.

    Article  CAS  PubMed  Google Scholar 

  123. Yamada Y, Nakatani H, Yanaihara H, Omote M. Phase I clinical trial of 99mTc-etarfolatide, an imaging agent for folate receptor in healthy Japanese adults. Ann Nucl Med. 2015;29:792–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Unit, “Maggiore della Carità” University Hospital, Corso Mazzini 18, 28100, Novara, Italy

    Federica Orsini & Erinda Puta

  2. Regional Center of Nuclear Medicine, University of Pisa, Pisa, 56126, Italy

    Federica Guidoccio & Giuliano Mariani

Authors
  1. Federica Orsini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Federica Guidoccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erinda Puta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuliano Mariani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Federica Orsini .

Editor information

Editors and Affiliations

  1. Attending Emeritus, Memorial Sloan-Kettering Cancer Center Dept. Radiology, New York, New York, USA

    H. William Strauss

  2. Professor Emeritus, University of Pisa, Pisa, Italy

    Giuliano Mariani

  3. Associate Professor and Director of Nuclear Medicine, University of Pisa, Pisa, Italy

    Duccio Volterrani

  4. Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

    Steven M. Larson

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing AG

About this entry

Cite this entry

Orsini, F., Guidoccio, F., Puta, E., Mariani, G. (2016). Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications. In: Strauss, H., Mariani, G., Volterrani, D., Larson, S. (eds) Nuclear Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-26067-9_3-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26067-9_3-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Online ISBN: 978-3-319-26067-9

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications
    Published:
    09 July 2022

    DOI: https://doi.org/10.1007/978-3-319-26067-9_3-3

  2. Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications
    Published:
    02 April 2022

    DOI: https://doi.org/10.1007/978-3-319-26067-9_3-2

  3. Original

    Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications
    Published:
    13 October 2016

    DOI: https://doi.org/10.1007/978-3-319-26067-9_3-1

Search

Navigation